Neurocrine Biosciences (NBIX)

6.45 -0.08  -1.23%  May 30, 8:00PM Go Pro
Watch this stock
View Full Chart NBIX Price Chart

Key Stats

Market Cap 427.25M
Revenue Growth -9.95%
Profit Margin -7.86%
Earnings Yield 9.46%
Dividend Yield 0.00%
Earnings Per Share TTM 0.61
PE Ratio 10.57
Price / Sales Ratio 5.609
52 Week High 9.98
52 Week Low 5.42
Beta 0.2987
View Pro Ratings Details

YCharts Pro Ratings

Go Pro.
Learn More
  • Pro Value Score Go Pro
  • Pro Fundamental Score Go Pro
  • Pro Valuation from Historical Multiples Go Pro

News

May 29 Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference PR Newswire
May 24 NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Submission of Matters to a Vote of Sec...
May 22 7 Undervalued Healthcare Stocks Being Bought Up By Hedge Funds
May 17 Neurocrine Biosciences Announces Urocortin 2 Phase II Study Results in Patients With ...
May 17 Neurocrine Biosciences Announces Urocortin 2 Phase II Study Results in Patients With ...
May 16 RT @adamfeuerstein Orbimed Advisors top 5 new buys in Q1: $ONXX $CCXI $IMGN $NBIX $ARRY, per 13F #biotech by WolfsBiotechs
May 09 Neurocrine Biosciences' CEO Presents at Deutsche Bank 37th Annual Health Care Confere...
May 09 Listen to $NBIX at deutsche bank ag health care conference - live at 11:20 AM, ondemand after - http://stks.co/3kDQ by earningscast
May 04 Neurocrine Biosciences To Present At The Deutsche Bank 37th Annual Health Care Confer...
May 04 Neurocrine Biosciences $NBIX in the MFI screen today. Small drug developer. Looks like a one-time revenue case, not certain though. by MagicDiligence
May 03 $NBIX 200 Day SMA Cross - Price crossed below 200 day SMA (7.2892). Confirmed by volume. by TradeIdeasQuant
May 02 $NBIX filed latest Quarterly Report http://stks.co/3dNP by MarketBrief

Profile

Exchange: NASDAQGS       Sector: Healthcare       Industry: Biotechnology

1 Year Total Return Performance

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Neurocrine Biosciences is down 21.82% over the last year vs S&P 500 Total Return up 0.88%, BioLineRx up 0.00%, and Achillion Pharmaceuticals up 0.27%.

  • NBIX Total Returns
  • ^SPXTR Total Returns
  • BLRX Total Returns
  • ACHN Total Returns

Fundamentals

Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.

Income Statement View Statement

Balance Sheet View Statement

Get Quote for

Pro Strategies Featuring NBIX

Did Neurocrine Biosciences make it into our Pro Portfolio Strategies?

Start your YCharts Pro membership now to find out.

NBIX Charts

Recent Quotes

Symbol Price Chg Chg % Market Cap
NBIX 6.45 -0.08 -1.23% 427.25M
NBG 1.44 -0.08 -5.26% 1.377B
MOC 1.10 +0.01 +0.92% 11.81M
MOBI 2.11 -0.08 -3.65% 67.88M
MO 32.02 -0.11 -0.34% 65.50B
MNTG 4.90 +0.11 +2.30% 135.58M
MNTA 13.83 -0.14 -1.00% 709.89M
MNST 73.64 +0.60 +0.82% 12.84B
MNRO 34.12 -0.34 -0.99% 1.053B
MNRK 9.95 +0.00 +0.00% 59.10M
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close